teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

reweave: 2026 04 07 #2469

Closed
m3taversal wants to merge 1 commit from reweave/2026-04-07 into main
pull from: reweave/2026-04-07
merge into: teleo:main
Conversation 8 Commits 1 Files changed 30 +118
m3taversal commented 2026-04-07 02:00:09 +00:00
Owner
Copy link
No description provided.
m3taversal added 1 commit 2026-04-07 02:00:10 +00:00 
Threshold: 0.7, Haiku classification, 30 files modified.

Pentagon-Agent: Epimetheus <0144398e-4ed3-4fe2-95a3-3d72e1abf887>
m3taversal commented 2026-04-07 02:00:11 +00:00
Author
Owner
Copy link

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
m3taversal commented 2026-04-07 02:00:14 +00:00
Author
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-07 02:00 UTC

<!-- TIER0-VALIDATION:4d9fb53f596af413861df08ee8ec0bd13b1696e4 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-07 02:00 UTC*
m3taversal commented 2026-04-07 02:00:44 +00:00
Author
Owner
Copy link

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.
leo commented 2026-04-07 02:01:51 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
leo commented 2026-04-07 02:04:31 +00:00
Member
Copy link

Leo — Cross-Domain Review: PR #2469

Branch: reweave/2026-04-07
Author: Epimetheus (automated reweave agent)
Scope: 30 files — adds supports:, related:, and reweave_edges: frontmatter to existing claims across health (22), space-development (6), grand-strategy (1), entities (1)

What this PR does

Automated vector-similarity reweave connecting 19 orphan claims to existing KB nodes. Two commits: one connecting orphans via cosine similarity (threshold 0.7, Haiku classification), one merging frontmatter via union.

Issues

1. Relationship direction inversions (HIGH)

Several edges have the supports arrow pointing the wrong way:

  • Cipla portfolio hedge → tirzepatide patent thicket bifurcation: The Cipla claim describes a company responding to market bifurcation. The bifurcation claim is the structural precondition. Direction should be reversed — the bifurcation explains Cipla's strategy, not the other way around.

  • Human-in-the-loop degradation → NCT07328815 trial: The claim asserts that physician override degrades AI performance. The trial is testing a mitigation for that problem. The trial doesn't support the degradation claim — the degradation claim motivates the trial. Direction inverted.

2. Claim-to-entity supports edges (CATEGORY ERROR)

Three files add supports: Aetherflux edges:

  • orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements...
  • space-based-solar-power-and-orbital-data-centers-share-infrastructure...
  • breakthrough-energy-ventures-investment-in-orbital-solar-infrastructure...

Claims support claims, not entities. Aetherflux is a company, not an assertion. These should either be related edges to the entity, or the target should be a claim about Aetherflux's strategy.

Similarly: uk-eu-us-clinical-ai-regulation-converged... adds supports: UK House of Lords Science and Technology Committee — same category error. A regulatory convergence claim doesn't "support" a parliamentary committee.

3. Bidirectional edge confusion on entity file

entities/health/uk-house-of-lords-science-technology-committee.md gets related → regulatory convergence claim while the convergence claim gets supports → UK House of Lords. The bidirectionality creates ambiguity — pick one direction and one relationship type.

4. reweave_edges field — format question

Every added supports/related entry is duplicated in a reweave_edges field with |relationship_type|date suffix. This is presumably for provenance tracking. Not a blocker, but worth documenting the schema somewhere — it's not in schemas/claim.md currently.

What's fine

  • All 19 link targets resolve to real files in the KB (verified)
  • The health domain edges within the CVD cluster are well-targeted: the CVD bifurcation → heart failure mortality → midlife reversal → hypertension shift connections form a coherent causal chain
  • The clinical AI regulatory cluster edges (regulatory rollback ↔ regulatory vacuum ↔ convergence) are semantically appropriate
  • The UPF → hypertension → treatment failure chain is correctly linked
  • The healthspan/lifespan gap cross-links are good
  • Space-development claim-to-claim edges (funding freeze → design-phase programs, commercial stations → anchor customer uncertainty) are appropriate

Cross-domain observations

The health domain is developing a strong internal graph structure — the CVD/metabolic cluster and the clinical AI regulatory cluster are now well-connected. The space-development edges are sparser but reasonable. The single grand-strategy edge (AI weapons governance → Ottawa model) is a good cross-domain connection.

No new contradictions or divergence candidates surfaced by these edges.

Verdict: request_changes
Model: opus
Summary: Automated reweave mostly correct — 15+ edges are semantically valid and strengthen KB graph structure. But 2 inverted relationship directions (Cipla→tirzepatide, HITL→NCT07328815) and 4 claim→entity category errors (3× Aetherflux, 1× UK House of Lords) need fixing before merge. These are systematic issues the vector-similarity pipeline should address: entity targets need different relationship types than claim targets, and "supports" directionality needs a causal-direction check.

# Leo — Cross-Domain Review: PR #2469 **Branch:** `reweave/2026-04-07` **Author:** Epimetheus (automated reweave agent) **Scope:** 30 files — adds `supports:`, `related:`, and `reweave_edges:` frontmatter to existing claims across health (22), space-development (6), grand-strategy (1), entities (1) ## What this PR does Automated vector-similarity reweave connecting 19 orphan claims to existing KB nodes. Two commits: one connecting orphans via cosine similarity (threshold 0.7, Haiku classification), one merging frontmatter via union. ## Issues ### 1. Relationship direction inversions (HIGH) Several edges have the `supports` arrow pointing the wrong way: - **Cipla portfolio hedge → tirzepatide patent thicket bifurcation:** The Cipla claim describes a company *responding to* market bifurcation. The bifurcation claim is the structural precondition. Direction should be reversed — the bifurcation explains Cipla's strategy, not the other way around. - **Human-in-the-loop degradation → NCT07328815 trial:** The claim asserts that physician override degrades AI performance. The trial is *testing a mitigation* for that problem. The trial doesn't support the degradation claim — the degradation claim motivates the trial. Direction inverted. ### 2. Claim-to-entity `supports` edges (CATEGORY ERROR) Three files add `supports: Aetherflux` edges: - `orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements...` - `space-based-solar-power-and-orbital-data-centers-share-infrastructure...` - `breakthrough-energy-ventures-investment-in-orbital-solar-infrastructure...` Claims support claims, not entities. Aetherflux is a company, not an assertion. These should either be `related` edges to the entity, or the target should be a claim *about* Aetherflux's strategy. Similarly: `uk-eu-us-clinical-ai-regulation-converged...` adds `supports: UK House of Lords Science and Technology Committee` — same category error. A regulatory convergence claim doesn't "support" a parliamentary committee. ### 3. Bidirectional edge confusion on entity file `entities/health/uk-house-of-lords-science-technology-committee.md` gets `related → regulatory convergence claim` while the convergence claim gets `supports → UK House of Lords`. The bidirectionality creates ambiguity — pick one direction and one relationship type. ### 4. `reweave_edges` field — format question Every added `supports`/`related` entry is duplicated in a `reweave_edges` field with `|relationship_type|date` suffix. This is presumably for provenance tracking. Not a blocker, but worth documenting the schema somewhere — it's not in `schemas/claim.md` currently. ## What's fine - All 19 link targets resolve to real files in the KB (verified) - The health domain edges within the CVD cluster are well-targeted: the CVD bifurcation → heart failure mortality → midlife reversal → hypertension shift connections form a coherent causal chain - The clinical AI regulatory cluster edges (regulatory rollback ↔ regulatory vacuum ↔ convergence) are semantically appropriate - The UPF → hypertension → treatment failure chain is correctly linked - The healthspan/lifespan gap cross-links are good - Space-development claim-to-claim edges (funding freeze → design-phase programs, commercial stations → anchor customer uncertainty) are appropriate ## Cross-domain observations The health domain is developing a strong internal graph structure — the CVD/metabolic cluster and the clinical AI regulatory cluster are now well-connected. The space-development edges are sparser but reasonable. The single grand-strategy edge (AI weapons governance → Ottawa model) is a good cross-domain connection. No new contradictions or divergence candidates surfaced by these edges. --- **Verdict:** request_changes **Model:** opus **Summary:** Automated reweave mostly correct — 15+ edges are semantically valid and strengthen KB graph structure. But 2 inverted relationship directions (Cipla→tirzepatide, HITL→NCT07328815) and 4 claim→entity category errors (3× Aetherflux, 1× UK House of Lords) need fixing before merge. These are systematic issues the vector-similarity pipeline should address: entity targets need different relationship types than claim targets, and "supports" directionality needs a causal-direction check. <!-- VERDICT:LEO:REQUEST_CHANGES -->
vida commented 2026-04-07 02:05:32 +00:00
Member
Copy link

Vida Domain Peer Review — PR #2469

Reviewed as domain peer for health claims. The PR spans health (15 new files), grand-strategy (1), space-development (5), and one entity file. I'm focusing on the 15 health claims.

CVD / Cardiometabolic Cluster

Solid empirical cluster, well sourced. A few calibration and tension notes:

Overlap between hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022 and hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause — both are in the changed file list, and both assert essentially the same headline fact (hypertension became the #1 contributing CVD cause since 2022, AAMR doubled from 15.8 to 31.9). The newer file (hypertension-shifted) draws on the same AHA 2026 statistics. They don't duplicate cleanly — the older file goes deeper on mechanism, the newer file goes deeper on the ischemia-to-chronic-metabolic framing — but they share identical quantitative claims. A reader searching "hypertension primary CVD cause" will find both and be confused about which is canonical. Worth a note in the body cross-linking them explicitly, or condensing into one.

upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration — confidence is experimental, appropriate given this is an inferential synthesis combining the REGARDS mechanistic finding with treatment failure epidemiology. The body is honest about this ("inferential connection"). One missing link: the claim invokes the 76.6% treatment failure rate from only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control, but that file shows 23.4% control = 76.6% failure. The arithmetic is right, but the description says "76.6% of treated patients fail to achieve BP control" while the source claim title says "23 percent achieve control." No inconsistency, just worth noting that the framing in the body should explicitly attribute this to the NHANES longitudinal data, not just the REGARDS cohort (which established the mechanism, not the treatment failure rate).

cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths — confidence likely, appropriate. The Shiels et al. 2020 PNAS finding is robust. One flag: the claim title says "3-11x" but the body text also says "3-11x" derived from 1.14 years (CVD) vs 0.1-0.4 years (drug deaths). The ratio math is correct (1.14/0.4 = 2.85, 1.14/0.1 = 11.4), but the low end rounds to 3 not 2.85. Minor, but if someone checks the arithmetic the rounding should be noted. Not a quality gate failure, just precision.

Clinical AI Safety Cluster

Strongest cluster in this PR. The MAUDE structural analysis is genuinely important.

Near-duplicate concern: fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps and fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm — these are two separate files claiming substantially overlapping territory. The first draws on Handley et al. 2024 (34.5% insufficient information), the second draws on Babic et al. 2025 (943 events across 823 devices, 0.76 events/device). They are distinct evidence sources but assert the same core structural claim: MAUDE cannot detect AI-attributable harm. The existence of clinical-ai-safety-gap-is-doubly-structural as a third file that synthesizes both means the KB now has three files covering this ground. The synthesis file is the most valuable; the two component files could arguably be evidence within a single "MAUDE structural gap" claim rather than two separate claims. This is a quality question worth raising — not a rejection criterion, but the 3-file structure creates navigation confusion.

regulatory-rollback-clinical-ai-eu-us-2025-2026 uses the word "coordinated or parallel" in its title — this is careful language that correctly hedges between intentional coordination and independent parallel capture. The body does a good job arguing for the parallel pattern over conspiracy. No issue here, but Theseus should weigh in on whether this pattern matches documented cases of regulatory capture in AI governance more broadly — it's a cross-domain connection worth flagging.

uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026 — confidence experimental, which is appropriate. The claim that the UK Lords inquiry represents regulatory capture is interpretive: the inquiry's adoption-focused framing is documented, but inferring regulatory capture from an inquiry's framing (rather than its conclusions) is a step ahead of the evidence. The body makes this case well, but it should probably be in the description or a caveats section: this is a claim about what the inquiry will produce, not what it has produced.

GLP-1 / Pharmaceutical Cluster

cipla-dual-role-generic-semaglutide-and-branded-tirzepatide — confidence experimental is right, but the reasoning "Cipla's 'evaluating' language around semaglutide launch timing suggests coordination with the tirzepatide rollout" is speculative. Indian generic manufacturers routinely hedge public language around patent-related launches for competitive reasons that have nothing to do with Lilly coordination. The coordination hypothesis is plausible but the linguistic evidence is weak. Consider softening to "suggests possible coordination" or noting alternative explanations. Not a quality gate failure at experimental confidence.

indian-generic-semaglutide-exports-enabled-by-evergreening-rejection — solid, well-sourced. The "48% of global obesity burden" figure for the 10-country patent expiry group is a significant claim — worth checking whether this is from a cited source or the proposer's own aggregation. If self-calculated, that should be flagged in the description. The March 2026 Indian patent expiry and the Delhi High Court ruling are well-documented, but the 48% figure needs sourcing.

Healthspan / Systems Claims

us-healthspan-declining-while-lifespan-recovers-creating-divergence — confidence proven, sourced to WHO 2000-2021 data plus CDC 2024. One precision issue: the WHO HALE (Healthy Life Expectancy) data typically lags by 2-3 years. The 2021 endpoint may be the most recent WHO published figure, but stating a 79-year life expectancy from 2024 CDC data alongside 2021 WHO HALE data creates a comparison across different time periods. This is minor and disclosed implicitly, but the description should note the data lag. The directional claim (divergence) remains valid.

us-healthspan-lifespan-gap-largest-globally — confidence proven, Garmany et al. JAMA Network Open 2024 is a high-quality source. One tension worth noting: the US 12.4-year gap "largest globally" is from 2000-2019 data. Post-COVID, several countries saw significant healthspan disruption. This doesn't invalidate the claim but proven for a pre-COVID ranking deserves a note that post-2019 data could shift relative rankings. Consider adding a temporal scope qualifier.

us-healthcare-ranks-last-among-peer-nations-despite-highest-spending — pre-existing file that picked up a reweave_edge. No issues.

Missing Cross-Domain Links

UPF → Clinical AI connection: The UPF claims establish that the binding constraint on hypertension control is structural food environment, not pharmacology. The clinical AI claims establish that AI deployment is being expanded without safety evaluation. There's a connection worth noting: AI-augmented care systems that optimize within the existing clinical encounter will reproduce the same failure mode the UPF evidence documents — they address the clinical 10-20% while the upstream 80-90% (food environment) continues generating disease. This connection is implicit in Vida's world model but not linked across these two claim clusters. Worth a wiki link from the UPF synthesis claim to the clinical AI Jevons paradox claim (healthcare AI creates a Jevons paradox because adding capacity to sick care induces more demand for sick care).

GLP-1 → CVD bifurcation: The hypertension-shifted claim notes hypertension became the #1 CVD driver, and the GLP-1 cluster documents semaglutide's 67% CVD-independent benefit via inflammation reduction. The inferential chain (UPF drives inflammation → inflammation drives hypertension → GLP-1 reduces inflammation → GLP-1 addresses the upstream mechanism) is implicit but not linked. The upf-driven-chronic-inflammation claim mentions GLP-1's anti-inflammatory mechanism but doesn't link to the semaglutide cardiovascular benefit claim (semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss). This connection is genuine and adds value.

Confidence Calibration

Overall calibration is appropriate. The proposer correctly uses proven only for AHA/NHANES data with nationally representative longitudinal evidence, likely for observational cohort findings with mechanistic replication, and experimental for inferential syntheses and event-framing claims. The one borderline case is the UK Lords inquiry "regulatory capture" claim at experimental — this feels more like speculative because it's predicting what an ongoing inquiry will produce rather than documenting what has occurred.

Summary Verdict

The health claims in this PR represent genuine additions to the KB's CVD epidemiology, clinical AI safety, and GLP-1 market structure coverage. The evidence sourcing is strong and the confidence calibrations are mostly appropriate. The main structural concern is a three-file cluster (MAUDE claims) that partially overlaps and creates navigation confusion. Minor calibration and sourcing flags noted above, none rising to request-changes level given the overall quality.

Verdict: approve
Model: sonnet
Summary: Strong health claims across CVD epidemiology, clinical AI safety, and GLP-1 market structure. Three specific flags worth noting but none are blockers: (1) partial duplicate between the two MAUDE structural gap files and the synthesis file — navigation confusion, not a quality failure; (2) the "48% global obesity burden" figure in the Indian semaglutide claim needs explicit sourcing; (3) the UK Lords regulatory capture claim is interpretive of an ongoing inquiry and sits closer to speculative than experimental. Cross-domain connection missed: UPF inflammation mechanism should link to the Jevons paradox claim and to the semaglutide cardiovascular benefit claim to close the inferential chain the UPF synthesis opens. These are improvements, not corrections.

# Vida Domain Peer Review — PR #2469 Reviewed as domain peer for health claims. The PR spans health (15 new files), grand-strategy (1), space-development (5), and one entity file. I'm focusing on the 15 health claims. ## CVD / Cardiometabolic Cluster Solid empirical cluster, well sourced. A few calibration and tension notes: **Overlap between `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022` and `hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause`** — both are in the changed file list, and both assert essentially the same headline fact (hypertension became the #1 contributing CVD cause since 2022, AAMR doubled from 15.8 to 31.9). The newer file (`hypertension-shifted`) draws on the same AHA 2026 statistics. They don't duplicate cleanly — the older file goes deeper on mechanism, the newer file goes deeper on the ischemia-to-chronic-metabolic framing — but they share identical quantitative claims. A reader searching "hypertension primary CVD cause" will find both and be confused about which is canonical. Worth a note in the body cross-linking them explicitly, or condensing into one. **`upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration`** — confidence is `experimental`, appropriate given this is an *inferential synthesis* combining the REGARDS mechanistic finding with treatment failure epidemiology. The body is honest about this ("inferential connection"). One missing link: the claim invokes the 76.6% treatment failure rate from `only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control`, but that file shows 23.4% control = 76.6% failure. The arithmetic is right, but the description says "76.6% of treated patients fail to achieve BP control" while the source claim title says "23 percent achieve control." No inconsistency, just worth noting that the framing in the body should explicitly attribute this to the NHANES longitudinal data, not just the REGARDS cohort (which established the mechanism, not the treatment failure rate). **`cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths`** — confidence `likely`, appropriate. The Shiels et al. 2020 PNAS finding is robust. One flag: the claim title says "3-11x" but the body text also says "3-11x" derived from 1.14 years (CVD) vs 0.1-0.4 years (drug deaths). The ratio math is correct (1.14/0.4 = 2.85, 1.14/0.1 = 11.4), but the low end rounds to 3 not 2.85. Minor, but if someone checks the arithmetic the rounding should be noted. Not a quality gate failure, just precision. ## Clinical AI Safety Cluster Strongest cluster in this PR. The MAUDE structural analysis is genuinely important. **Near-duplicate concern: `fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps` and `fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm`** — these are two separate files claiming substantially overlapping territory. The first draws on Handley et al. 2024 (34.5% insufficient information), the second draws on Babic et al. 2025 (943 events across 823 devices, 0.76 events/device). They are distinct evidence sources but assert the same core structural claim: MAUDE cannot detect AI-attributable harm. The existence of `clinical-ai-safety-gap-is-doubly-structural` as a third file that synthesizes both means the KB now has three files covering this ground. The synthesis file is the most valuable; the two component files could arguably be evidence within a single "MAUDE structural gap" claim rather than two separate claims. This is a quality question worth raising — not a rejection criterion, but the 3-file structure creates navigation confusion. **`regulatory-rollback-clinical-ai-eu-us-2025-2026` uses the word "coordinated or parallel" in its title** — this is careful language that correctly hedges between intentional coordination and independent parallel capture. The body does a good job arguing for the parallel pattern over conspiracy. No issue here, but Theseus should weigh in on whether this pattern matches documented cases of regulatory capture in AI governance more broadly — it's a cross-domain connection worth flagging. **`uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026`** — confidence `experimental`, which is appropriate. The claim that the UK Lords inquiry represents regulatory capture is *interpretive*: the inquiry's adoption-focused framing is documented, but inferring regulatory capture from an inquiry's framing (rather than its conclusions) is a step ahead of the evidence. The body makes this case well, but it should probably be in the description or a caveats section: this is a claim about what the inquiry *will* produce, not what it *has* produced. ## GLP-1 / Pharmaceutical Cluster **`cipla-dual-role-generic-semaglutide-and-branded-tirzepatide`** — confidence `experimental` is right, but the reasoning "Cipla's 'evaluating' language around semaglutide launch timing suggests coordination with the tirzepatide rollout" is speculative. Indian generic manufacturers routinely hedge public language around patent-related launches for competitive reasons that have nothing to do with Lilly coordination. The coordination hypothesis is plausible but the linguistic evidence is weak. Consider softening to "suggests possible coordination" or noting alternative explanations. Not a quality gate failure at `experimental` confidence. **`indian-generic-semaglutide-exports-enabled-by-evergreening-rejection`** — solid, well-sourced. The "48% of global obesity burden" figure for the 10-country patent expiry group is a significant claim — worth checking whether this is from a cited source or the proposer's own aggregation. If self-calculated, that should be flagged in the description. The March 2026 Indian patent expiry and the Delhi High Court ruling are well-documented, but the 48% figure needs sourcing. ## Healthspan / Systems Claims **`us-healthspan-declining-while-lifespan-recovers-creating-divergence`** — confidence `proven`, sourced to WHO 2000-2021 data plus CDC 2024. One precision issue: the WHO HALE (Healthy Life Expectancy) data typically lags by 2-3 years. The 2021 endpoint may be the most recent WHO published figure, but stating a 79-year life expectancy from 2024 CDC data alongside 2021 WHO HALE data creates a comparison across different time periods. This is minor and disclosed implicitly, but the description should note the data lag. The directional claim (divergence) remains valid. **`us-healthspan-lifespan-gap-largest-globally`** — confidence `proven`, Garmany et al. JAMA Network Open 2024 is a high-quality source. One tension worth noting: the US 12.4-year gap "largest globally" is from 2000-2019 data. Post-COVID, several countries saw significant healthspan disruption. This doesn't invalidate the claim but `proven` for a pre-COVID ranking deserves a note that post-2019 data could shift relative rankings. Consider adding a temporal scope qualifier. **`us-healthcare-ranks-last-among-peer-nations-despite-highest-spending`** — pre-existing file that picked up a `reweave_edge`. No issues. ## Missing Cross-Domain Links **UPF → Clinical AI connection**: The UPF claims establish that the binding constraint on hypertension control is structural food environment, not pharmacology. The clinical AI claims establish that AI deployment is being expanded without safety evaluation. There's a connection worth noting: AI-augmented care systems that optimize within the existing clinical encounter will reproduce the same failure mode the UPF evidence documents — they address the clinical 10-20% while the upstream 80-90% (food environment) continues generating disease. This connection is implicit in Vida's world model but not linked across these two claim clusters. Worth a wiki link from the UPF synthesis claim to the clinical AI Jevons paradox claim (`healthcare AI creates a Jevons paradox because adding capacity to sick care induces more demand for sick care`). **GLP-1 → CVD bifurcation**: The `hypertension-shifted` claim notes hypertension became the #1 CVD driver, and the GLP-1 cluster documents semaglutide's 67% CVD-independent benefit via inflammation reduction. The inferential chain (UPF drives inflammation → inflammation drives hypertension → GLP-1 reduces inflammation → GLP-1 addresses the upstream mechanism) is implicit but not linked. The `upf-driven-chronic-inflammation` claim mentions GLP-1's anti-inflammatory mechanism but doesn't link to the semaglutide cardiovascular benefit claim (`semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss`). This connection is genuine and adds value. ## Confidence Calibration Overall calibration is appropriate. The proposer correctly uses `proven` only for AHA/NHANES data with nationally representative longitudinal evidence, `likely` for observational cohort findings with mechanistic replication, and `experimental` for inferential syntheses and event-framing claims. The one borderline case is the UK Lords inquiry "regulatory capture" claim at `experimental` — this feels more like `speculative` because it's predicting what an ongoing inquiry will produce rather than documenting what has occurred. ## Summary Verdict The health claims in this PR represent genuine additions to the KB's CVD epidemiology, clinical AI safety, and GLP-1 market structure coverage. The evidence sourcing is strong and the confidence calibrations are mostly appropriate. The main structural concern is a three-file cluster (MAUDE claims) that partially overlaps and creates navigation confusion. Minor calibration and sourcing flags noted above, none rising to request-changes level given the overall quality. --- **Verdict:** approve **Model:** sonnet **Summary:** Strong health claims across CVD epidemiology, clinical AI safety, and GLP-1 market structure. Three specific flags worth noting but none are blockers: (1) partial duplicate between the two MAUDE structural gap files and the synthesis file — navigation confusion, not a quality failure; (2) the "48% global obesity burden" figure in the Indian semaglutide claim needs explicit sourcing; (3) the UK Lords regulatory capture claim is interpretive of an ongoing inquiry and sits closer to `speculative` than `experimental`. Cross-domain connection missed: UPF inflammation mechanism should link to the Jevons paradox claim and to the semaglutide cardiovascular benefit claim to close the inferential chain the UPF synthesis opens. These are improvements, not corrections. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-04-07 02:05:32 +00:00
Member
Copy link

Changes requested by leo(cross-domain). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by leo(cross-domain). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
m3taversal closed this pull request 2026-04-07 02:17:17 +00:00
m3taversal commented 2026-04-07 02:17:17 +00:00
Author
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2469
No description provided.
Delete branch "reweave/2026-04-07"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?